隐性营养不良型大疱性表皮松解症患者接受基因矫正自体表皮移植后的安全性与创面结局
美国单中心1期临床试验纳入4例重度隐性营养不良型大疱性表皮松解症(RDEB)患者,将携带全长人COL7A1的逆转录病毒转导的自体角质形成细胞构建成表皮片移植到24处创面。所有移植耐受良好,无严重不良事件;移植部位VII型胶原表达随时间下降,创面愈合率在3、6、12个月分别为87%、67%、50%,反应因人因部位而异。
要点
- 4例RDEB患者共24处移植均耐受良好,未发生严重不良事件。
- 移植部位VII型胶原表达3个月为90%(9/10)、6个月为66%(8/12)、12个月为42%(5/12)。
- 创面愈合≥75%的比例3个月为87%(21/24)、6个月为67%(16/24)、12个月为50%(12/24)。
核心结论
- 在这项4例RDEB患者的初步研究中,部分VII型胶原基因矫正移植片出现创面愈合,但反应在患者之间和移植部位之间可变,且总体上在1年内下降。
- 需要对这些患者进行长期随访,并需要开展纳入更广泛患者的对照试验,以更好地了解基因矫正自体表皮移植的潜在长期疗效。
研究设计与样本
- 美国单中心1期临床试验,纳入4例重度RDEB患者,移植适合的创面面积至少100 cm2,排除角质形成细胞VII型胶原表达检测不到的患者。
- 从4例患者活检样本分离自体角质形成细胞,用携带全长人COL7A1的生产质量管理规范级逆转录病毒转导并组装成表皮片移植,每例患者6处创面,共24处移植。
主要发现
- 4例患者均为男性,平均年龄23岁(范围18-32岁),估计RDEB累及体表面积4%至30%。
- 所有24处移植均耐受良好,无严重不良事件。
- 免疫荧光显微镜显示移植部位真皮-表皮交界处VII型胶原表达:3个月10份活检中9份(90%)、6个月12份中8份(66%)、12个月12份中5份(42%),包括VII型胶原正确定位于锚定原纤维。
- 重组VII型胶原移植部位创面愈合≥75%的比例:3个月24处中21处(87%)、6个月24处中16处(67%)、12个月24处中12处(50%),与基线创面比较。
关键数值与推荐
- 主要安全性结局为复制 competent 逆转录病毒、癌症和自身免疫反应。
- 分子矫正以免疫荧光和免疫电子显微镜测量的VII型胶原表达评估。
- 创面愈合通过移植后3、6、12个月连续拍照评估。
局限性
- 原文指出这是4例患者的初步研究。
- 原文指出反应在患者之间和移植部位之间可变,且一般在1年内下降。
- 原文指出需要对这些患者进行长期随访。
- 原文指出需要开展纳入更广泛患者的对照试验以更好地了解潜在长期疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Recessive dystrophic epidermolysis bullosa (RDEB) is a devastating, often fatal, inherited blistering disorder caused by mutations in the COL7A1 gene encoding type VII collagen. Support and palliation are the only current therapies. OBJECTIVE: To evaluate the safety and wound outcomes following genetically corrected autologous epidermal grafts in patients with RDEB. DESIGN, SETTING, AND PARTICIPANTS: Single-center phase 1 clinical trial conducted in the United States of 4 patients with severe RDEB with a measured area of wounds suitable for grafting of at least 100 cm2. Patients with undetectable type VII collagen keratinocyte expression were excluded. INTERVENTIONS: Autologous keratinocytes isolated from biopsy samples collected from 4 patients with RDEB were transduced with good manufacturing practice-grade retrovirus carrying full-length human COL7A1 and assembled into epidermal sheet grafts. Type VII collagen gene-corrected grafts (approximately 35 cm2) were transplanted onto 6 wounds in each of the patients (n = 24 grafts). MAIN OUTCOMES AND MEASURES: The primary safety outcomes were recombination competent retrovirus, cancer, and autoimmune reaction. Molecular correction was assessed as type VII collagen expression measured by immunofluorescence and immunoelectron microscopy. Wound healing was assessed using serial photographs taken at 3, 6, and 12 months after grafting. RESULTS: The 4 patients (mean age, 23 years [range, 18-32 years]) were all male with an estimated body surface area affected with RDEB of 4% to 30%. All 24 grafts were well tolerated without serious adverse events. Type VII collagen expression at the dermal-epidermal junction was demonstrated on the graft sites by immunofluorescence microscopy in 9 of 10 biopsy samples (90%) at 3 months, in 8 of 12 samples (66%) at 6 months, and in 5 of 12 samples (42%) at 12 months, including correct type VII collagen localization to anchoring fibrils. Wounds with recombinant type VII collagen graft sites displayed 75% or greater healing at 3 months (21 intact graft sites of 24 wound sites; 87%), 6 months (16/24; 67%), and 12 months (12/24; 50%) compared with baseline wound sites. CONCLUSIONS AND RELEVANCE: In this preliminary study of 4 patients with RDEB, there was wound healing in some type VII collagen gene-corrected grafts, but the response was variable among patients and among grafted sites and generally declined over 1 year. Long-term follow-up is necessary for these patients, and controlled trials are needed with a broader range of patients to better understand the potential long-term efficacy of genetically corrected autologous epidermal grafts. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01263379.
引用
- Siprashvili Z, Nguyen NT, Gorell ES, et al. Safety and Wound Outcomes Following Genetically Corrected Autologous Epidermal Grafts in Patients With Recessive Dystrophic Epidermolysis Bullosa. JAMA. 2016. PMID: 27802546. doi:10.1001/jama.2016.15588
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。